Brian MBA - Immunocore Holdings CFO Strategy
| IMCR Stock | USD 32.74 0.09 0.27% |
Insider
Brian MBA is CFO Strategy of Immunocore Holdings
| Age | 57 |
| Address | 92 Park Drive, Abingdon, United Kingdom, OX14 4RY |
| Phone | 44 12 3543 8600 |
| Web | https://www.immunocore.com |
Immunocore Holdings Management Efficiency
The company has return on total asset (ROA) of (0.0522) % which means that it has lost $0.0522 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1283) %, meaning that it created substantial loss on money invested by shareholders. Immunocore Holdings' management efficiency ratios could be used to measure how well Immunocore Holdings manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/29/2024, Return On Tangible Assets is likely to drop to -0.1. In addition to that, Return On Capital Employed is likely to drop to -0.14. At this time, Immunocore Holdings' Net Tangible Assets are relatively stable compared to the past year. As of 11/29/2024, Non Currrent Assets Other is likely to grow to about 15.2 M, while Total Current Assets are likely to drop slightly above 270.4 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Sharon Townson | Monte Rosa Therapeutics | 49 | |
| Kristian MBA | Viridian Therapeutics | 49 | |
| Joo MD | Design Therapeutics | 61 | |
| Martin MD | Ventyx Biosciences | 49 | |
| MBA MBA | Vaxcyte | 63 | |
| Ashish MBA | Vaxcyte | 52 | |
| Jeff Fairman | Vaxcyte | 60 | |
| Dawn Giangiulio | Design Therapeutics | N/A | |
| John Nuss | Ventyx Biosciences | 65 | |
| Christopher MD | Arcellx | 44 | |
| Filip MD | Monte Rosa Therapeutics | 50 | |
| Michelle Gilson | Arcellx | 31 | |
| Jonathan MBA | Viridian Therapeutics | 49 | |
| Nik Chetwyn | Erasca Inc | N/A | |
| Prof MD | Ventyx Biosciences | N/A | |
| Dr Roberts | Lyra Therapeutics | 56 | |
| Chandra Lovejoy | Erasca Inc | 53 | |
| Wei MD | Erasca Inc | 54 | |
| Paul Ross | Mirum Pharmaceuticals | N/A | |
| MD MBA | Kalvista Pharmaceuticals | 51 | |
| Julie CPA | Design Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.13 | ||||
| Return On Asset | -0.0522 |
Immunocore Holdings Leadership Team
Elected by the shareholders, the Immunocore Holdings' board of directors comprises two types of representatives: Immunocore Holdings inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Immunocore. The board's role is to monitor Immunocore Holdings' management team and ensure that shareholders' interests are well served. Immunocore Holdings' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Immunocore Holdings' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Tina Leger, Chief Director | ||
| Sbastien Desprez, Head Communications | ||
| Debra Nielsen, Chief Staff | ||
| JD Esq, Chief Officer | ||
| Annelise Vuidepot, CTO Research | ||
| Brian MBA, CFO Strategy | ||
| Amy JudgePrein, Chief Officer | ||
| John III, Finance SVP | ||
| Bahija Jallal, CEO Director | ||
| Clayton Robertson, Head Relations | ||
| John MBA, SVP Officer | ||
| Lily Hepworth, General Secretary | ||
| David MD, Executive Development | ||
| JoAnn Suzich, Head Research | ||
| Sean Buckley, VP Officer |
Immunocore Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Immunocore Holdings a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.13 | ||||
| Return On Asset | -0.0522 | ||||
| Profit Margin | (0.16) % | ||||
| Operating Margin | (0.11) % | ||||
| Current Valuation | 1.22 B | ||||
| Shares Outstanding | 50.03 M | ||||
| Shares Owned By Insiders | 5.23 % | ||||
| Shares Owned By Institutions | 94.59 % | ||||
| Number Of Shares Shorted | 7.6 M | ||||
| Price To Book | 4.35 X |
Pair Trading with Immunocore Holdings
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Immunocore Holdings position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immunocore Holdings will appreciate offsetting losses from the drop in the long position's value.Moving against Immunocore Stock
| 0.46 | BHC | Bausch Health Companies | PairCorr |
| 0.35 | HCM | HUTCHMED DRC | PairCorr |
| 0.32 | EWTX | Edgewise Therapeutics | PairCorr |
The ability to find closely correlated positions to Immunocore Holdings could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Immunocore Holdings when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Immunocore Holdings - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Immunocore Holdings to buy it.
The correlation of Immunocore Holdings is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Immunocore Holdings moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Immunocore Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Immunocore Holdings can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Immunocore Stock Analysis
When running Immunocore Holdings' price analysis, check to measure Immunocore Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunocore Holdings is operating at the current time. Most of Immunocore Holdings' value examination focuses on studying past and present price action to predict the probability of Immunocore Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunocore Holdings' price. Additionally, you may evaluate how the addition of Immunocore Holdings to your portfolios can decrease your overall portfolio volatility.